Emergent BioSolutions

$90.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.48 (-4.73%) As of 6:36 PM UTC today

Why Robinhood?

You can buy or sell EBS and other stocks, options, and ETFs commission-free!

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD. The listed name for EBS is Emergent Biosolutions, Inc.

CEO
Robert G. Kramer
Employees
2,200
Headquarters
Gaithersburg, Maryland
Founded
1998
Market Cap
4.64B
Price-Earnings Ratio
17.51
Dividend Yield
—
Average Volume
915.63K
High Today
$94.78
Low Today
$89.90
Open Price
$93.01
Volume
430.88K
52 Week High
$137.61
52 Week Low
$46.37

EBS News

CNBC18h

Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually

As the U.S. makes headway in its coronavirus vaccination campaign, Emergent BioSolutions CEO Bob Kramer appeared on CNBC Wednesday to explain his company's role

EBS Earnings

-$0.12
$1.14
$2.41
$3.67
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$3.19 per share
Actual
$3.67 per share
Replay Earnings Call

You May Also Like

BIMI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure